ArticleGastroenterology & hepatology2017
The Enigma of Hepatitis E Virus.
Article in Gastroenterology & hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Seroprevalence of hepatitis E virus infection in pregnant women: a systematic review and meta-analysis.Annals of Saudi medicinePooled it
- Hepatitis E Virus Infection in a Hospital from Southern Romania-New Data About a Threat to Public Health.Microorganisms · 2025Article
- Cross-species transmission and histopathological variation in specific-pathogen-free minipigs infected with different hepatitis E virus strains.Veterinary research · 2024Article
- Testing Hepatitis E Seroprevalence among HIV-Infected Patients in Greece: The SHIP Study.Pathogens (Basel, Switzerland) · 2024Article
- The molecular epidemiology of hepatitis E virus genotype 3 in Canada.Epidemiology and infection · 2024Article
- The burden of hepatitis E virus infection among Ghanaian pregnant women.Frontiers in public health · 2024Article
- Hepatitis E associated determinants and diagnostic biomarkers during pregnancy and its prenatal consequences in Multan, Punjab tertiary care setting (Pakistan).American journal of translational research · 2024Article
- Repurposing of artesunate, an antimalarial drug, as a potential inhibitor of hepatitis E virus.Archives of virology · 2023Article
- Review
- Seroprevalence of Anti-Hepatitis E Virus Antibodies among Patients from a Tertiary Hospital from Northeast Romania.Medicina (Kaunas, Lithuania) · 2022Article
- Viral Hepatitis - The Road Traveled and the Journey Remaining.Hepatic medicine : evidence and research · 2022Review
- Hepatitis E Infection in a Longitudinal Cohort of Hepatitis C Virus and HCV/HIV Coinfected Persons.AIDS research and human retroviruses · 2021Article
- Enterically transmitted hepatitis in the third millennium in northeastern Romania.Experimental and therapeutic medicine · 2021Article
- Development and Clinical Validation of a Pangenotypic PCR-Based Assay for the Detection and Quantification of Hepatitis E Virus (Journal of clinical microbiology · 2021Article
- Prevalence of hepatitis E virus in children with acute hepatitis: one Egyptian center study.Germs · 2020Article
- Hepatitis E: What We Think We Know.Clinical liver disease · 2020Review
- Evaluation of High-Pressure Processing in Inactivation of the Hepatitis E Virus.Frontiers in microbiology · 2020Article
- Pathogenic mechanisms and current epidemiological status of HEV infection in asymptomatic blood donors and patients with chronic diseases.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Review
- Hepatitis E virus: advances and challenges.Nature reviews. Gastroenterology & hepatology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Globally, hepatitis E virus (HEV) is the most common cause of acute viral hepatitis. HEV is endemic in many developing countries, yet it is far more common in industrialized, nonendemic countries than previously recognized. Nonetheless, HEV remains poorly characterized and is frequently unidentified or misdiagnosed by clinicians. Manifestation of disease, source of infection, and route of transmission vary by HEV genotype and epidemiology in endemic and nonendemic settings worldwide. HEV infection can be acute or chronic, further complicating the presentation, diagnosis, prognosis, and natural history of disease. However, accurate identification and diagnosis of HEV has important implications for patient management, disease control, prevention efforts, and characterization of mechanisms of transmission and epidemiology. Acute HEV infection is rarely diagnosed in industrialized, nonendemic countries; however, recent seroprevalence data collected using modern, highly sensitive testing assays demonstrate a surprisingly high prevalence of anti-HEV antibodies in these settings, suggesting common subclinical or unrecognized infection. These data suggest widespread underestimation of the global burden, population seroprevalence, and importance of HEV infection. Enhanced capacity for disease recognition, accurate diagnosis, and clinical awareness are critical to improving the management and reducing the burden of HEV infection worldwide.
Indexed as
Identifiers
28867980PMC5572962What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.